Clinical Trial Update: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 open-label, uncontrolled study evaluating ONO-4578 and ONO-4538 in combination with standard first-line therapies (modified FOLFIRINOX or gemcitabine pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ONO-4538
• ONO-4578

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: COMPLETED